Ensysce Biosciences Inc Total Assets
Ensysce Biosciences Inc total assets. Based on the latest financial reports, Ensysce Biosciences Inc (ENSC) holds total assets worth $2.96 Million USD as of June 2026. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. Also see market value of Ensysce Biosciences Inc for the company's overall valuation and market capitalisation.
Total Assets of Ensysce Biosciences Inc (2017–2025)
Total assets of Ensysce Biosciences Inc from 2017 to 2025. This chart illustrates how Ensysce Biosciences Inc's total assets have evolved over time, based on quarterly financial data. See ENSC live share price for real-time trading data and today's change.
Ensysce Biosciences Inc - Asset Composition Analysis
Ensysce Biosciences Inc Total Assets Breakdown (December 2025)
Ensysce Biosciences Inc total assets breakdown as of December 2025. Ensysce Biosciences Inc's total assets of $2.96 Million consist of 97.2% current assets and 2.8% non-current assets.
| Asset Category | Amount (USD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 57.8% |
| Accounts Receivable | $420.35K | 5.6% |
| Inventory | $0.00 | 0.0% |
| Property, Plant & Equipment | $0.00 | 0.0% |
| Intangible Assets | $0.00 | 0.0% |
| Goodwill | $0.00 | 0.0% |
Asset Composition Trend (2017–2025)
This chart illustrates how Ensysce Biosciences Inc's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. Explore Ensysce Biosciences Inc (ENSC) liquidity to equity ratio to assess how much short-term liquidity the company maintains relative to its equity base.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Ensysce Biosciences Inc's current assets represent 97.2% of total assets in 2025, an increase from 1.1% in 2017.
- Cash Position: Cash and equivalents constituted 57.8% of total assets in 2025, up from 1.0% in 2017.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 0.0% of total assets, unchanged from 0.0% in 2017.
- Asset Diversification: The largest asset category is accounts receivable at 5.6% of total assets.
Ensysce Biosciences Inc Competitors by Total Assets
Key competitors of Ensysce Biosciences Inc based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
CSL LTD SPON.ADR 2
F:CSJA
|
Germany | €38.45 Billion |
|
Biomarin Pharmaceutical Inc
NASDAQ:BMRN
|
USA | $11.72 Billion |
|
Shanghai Allist Pharmaceuticals Co. Ltd. A
SHG:688578
|
China | CN¥8.59 Billion |
|
Xiamen Amoytop Biotech Co Ltd
SHG:688278
|
China | CN¥3.21 Billion |
|
Neuren Pharmaceuticals Ltd
AU:NEU
|
Australia | AU$331.25 Million |
|
PHARVARIS N.V. EO -12
F:9EN
|
Germany | €301.45 Million |
|
NANOBIOTIX S.A. SP.ADR
F:5NRA
|
Germany | €67.76 Million |
|
Chengdu Easton Biopharmaceuticals Co Ltd
SHG:688513
|
China | CN¥3.82 Billion |
Ensysce Biosciences Inc - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 0.70 | 2.10 | 1.27 |
| Quick Ratio | 0.70 | 2.10 | 1.27 |
| Cash Ratio | 0.00 | 0.88 | 0.97 |
| Working Capital | $-1.22 Million | $2.77 Million | $1.89 Million |
Ensysce Biosciences Inc - Advanced Valuation Insights
This section examines the relationship between Ensysce Biosciences Inc's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 0.86 |
| Latest Market Cap to Assets Ratio | 1.00 |
| Asset Growth Rate (YoY) | 33.1% |
| Total Assets | $7.45 Million |
| Market Capitalization | $7.43 Million USD |
Valuation Analysis
Near Book Valuation: The market values Ensysce Biosciences Inc's assets close to their book value (1.00x), suggesting investors view the company's assets at approximately fair value.
Rapid Asset Growth: Ensysce Biosciences Inc's assets grew by 33.1% over the past year, indicating significant expansion of the company's resource base.
Annual Total Assets for Ensysce Biosciences Inc (2017–2025)
The table below shows the annual total assets of Ensysce Biosciences Inc from 2017 to 2025.
| Year | Total Assets | Change |
|---|---|---|
| 2025-12-31 | $7.45 Million | +33.15% |
| 2024-12-31 | $5.60 Million | +106.69% |
| 2023-12-31 | $2.71 Million | -53.98% |
| 2022-12-31 | $5.89 Million | -64.15% |
| 2021-12-31 | $16.42 Million | +4566.58% |
| 2020-12-31 | $351.81K | -99.82% |
| 2019-12-31 | $196.51 Million | -4.06% |
| 2018-12-31 | $204.83 Million | +1.19% |
| 2017-12-31 | $202.43 Million | -- |
About Ensysce Biosciences Inc
Ensysce Biosciences, Inc., a clinical-stage pharmaceutical company, develops prescription drugs for severe pain relief in opioid misuse, abuse, and overdose in the United States. It develops products using Trypsin Activated Abuse Protection (TAAP) platform, designed to release clinically effective drugs only when exposed to specific physiological conditions; and Multi-Pill Abuse Resistance (MPAR)… Read more